EDGAR Filing Documents for 0001193125-24-117981

Form DEF 14A - Other definitive proxy statements:

SEC Accession No. 0001193125-24-117981

Filing Date

2024-04-26

Accepted

2024-04-26 16:06:21

Documents

Period of Report

2024-06-07

Interactive Data

Document Format Files

Seq	Description	Document	Type	Size
1	DEF 14A	d747644ddef14a.htm iXBRL	DEF 14A	877213
6	GRAPHIC	g747644g01g02.jpg	GRAPHIC	56899
7	GRAPHIC	g747644g56a01.jpg	GRAPHIC	80888
8	GRAPHIC	g747644g57a01.jpg	GRAPHIC	83167
9	GRAPHIC	g747644g83a01.jpg	GRAPHIC	214224
10	GRAPHIC	g747644g84a01.jpg	GRAPHIC	151232
	Complete submission text file	0001193125-24-117981.txt		3237960

Data Files

Seq	Description	Document	Type	Size
2	XBRL TAXONOMY EXTENSION SCHEMA	fate-20231231.xsd	EX-101.SCH	5723
3	XBRL TAXONOMY EXTENSION DEFINITION LINKBASE	fate-20231231_def.xml	EX-101.DEF	5837
4	XBRL TAXONOMY EXTENSION LABEL LINKBASE	fate-20231231_lab.xml	EX-101.LAB	8782
5	XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE	fate-20231231_pre.xml	EX-101.PRE	5314
23	EXTRACTED XBRL INSTANCE DOCUMENT	d747644ddef14a_htm.xml	XML	265610

Mailing Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131

Business Address 12278 SCRIPPS SUMMIT DRIVE SAN DIEGO CA 92131 858.875.1803

FATE THERAPEUTICS INC (Filer) CIK: 0001434316 (see all company filings)

IRS No.: 651311552 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36076 | Film No.: 24883611
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)